In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites
about
Causes, consequences and biomarkers of stress in swine: an updateElevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesisTumor-shed PGE(2) impairs IL2Rgammac-signaling to inhibit CD4 T cell survival: regulation by theaflavins.Interleukin-18 protects mice against acute herpes simplex virus type 1 infection.IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanismsUp-regulation of reactive oxygen species (ROS) and resistance to Fas-mediated apoptosis in the C33A cervical cancer cell line transfected with IL-18 receptor.The Nlrp3 inflammasome: contributions to intestinal homeostasis.Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives.IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation.NLRPs, microbiota, and gut homeostasis: unravelling the connection.Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα.Interleukin-1 beta and interleukin-18: regulation and activity in local inflammation.Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease.Inflammasomes and Intestinal TumorigenesisSynergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA.Immunotherapy of cancer by IL-12-based cytokine combinationsImmunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis.How diverse--CD4 effector T cells and their functions.Interleukins and cancer immunotherapy.Inflammasomes in carcinogenesis and anticancer immune responses.Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.Interleukin-18 induces acute biphasic reduction in the levels of circulating leukocytes in mice.Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis.Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis.Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model.Effect of interleukin-18 on mouse core body temperature.Evaluation of interleukin-18 production by in vitro differentiated monocytes from breast cancer patients.IL-18 is produced by prostate cancer cells and secreted in response to interferons.Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18.Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18).Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18.Immunological effects of laparoscopic and open cholecystectomy.
P2860
Q26740268-1EBEFF94-6F62-4A80-98B7-D9FD731D94D6Q27489815-F1EED3D5-870F-484B-899F-CFAA4CC82E98Q33509284-FD213B9D-9BC4-4BC4-A38F-25F014FE871EQ33653786-40D4791A-A463-4592-B5E2-466F9D46DB4EQ34026026-211445AF-2B58-4CA3-A4EB-5AE419B6968FQ34327533-86DB86B6-D3DD-4969-8EBE-70ED936F360FQ34762033-CE4D651B-EFF4-4AED-A9D0-7DCE76CC064DQ35001511-3ECE8802-905A-44BB-85CB-9203D8736579Q35013368-4C35EE57-5B6B-4087-8373-DB77FDA79CFCQ35150890-81B163D5-7AE1-4333-80A7-E0B87609CA80Q35204881-EAAAF73B-4F7F-460D-B221-F95B79F10B29Q35755278-646AE84C-CE2C-417A-99FB-D9B73991EFD3Q35787184-32C96297-1751-43E0-8620-62EE69946AD8Q36072651-6FC79D4C-BF1D-4CBB-8CBA-121385AFC0DAQ36673092-5AA9DB60-1154-44AA-AAAF-06D8E1439EEDQ36724827-6FF30714-62E8-4AA6-99D0-4359F19083ABQ37315226-652CBDB9-7296-47C3-B4DB-5CF2AA7877CEQ37379687-EAD2AF81-7A72-4D33-9B4D-1E75AE613763Q37502276-6C6725DC-3944-46B8-989D-71B5F58EE736Q37773302-A37835FD-AFAC-4D30-8E6C-D2D505DD7E8EQ37995072-1208C4CD-7BC9-4EC1-85E1-0F73C6FC6A0DQ38073096-8DE4C6C2-CDF4-48A4-8C1A-494D50AD9007Q39625918-69C2A65F-5B90-47AA-BEA6-DF34E9F13CDBQ39842445-D22DF2D8-6EB4-44F3-8F8E-A97B2FE382F0Q40467969-FBF7CBCA-49BE-4F44-8908-3D7369E020A9Q40530022-94F0A229-D444-46E8-9868-464BAE3BD27BQ40588824-75BFD317-52C4-44EE-9AD9-7CDF36E3DB95Q40730147-13C3FD55-A760-4929-A9F8-EE862C5BDFC6Q44549275-432584C4-2BE7-469B-BBF0-D003A48F3E76Q45855495-DB8A409C-67CB-43B1-A039-FF7B5C928458Q45862547-81918881-6623-46CD-BBDD-9A59AEA873ADQ45876638-AE56D11A-4BB3-4D51-9031-83894A0CA43EQ46940975-52CEDE2E-91E2-4C62-A1C2-9DAA77B40B16Q48296275-7245B24F-B325-4987-8B31-2624F1E381C9
P2860
In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites
description
1997 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1997
@ast
im Januar 1997 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1997/01/01)
@sk
vědecký článek publikovaný v roce 1997
@cs
wetenschappelijk artikel (gepubliceerd op 1997/01/01)
@nl
наукова стаття, опублікована в січні 1997
@uk
مقالة علمية (نشرت عام 1997)
@ar
name
In vivo antitumor effects of m ...... th A sarcoma malignant ascites
@ast
In vivo antitumor effects of m ...... th A sarcoma malignant ascites
@en
In vivo antitumor effects of m ...... th A sarcoma malignant ascites
@nl
type
label
In vivo antitumor effects of m ...... th A sarcoma malignant ascites
@ast
In vivo antitumor effects of m ...... th A sarcoma malignant ascites
@en
In vivo antitumor effects of m ...... th A sarcoma malignant ascites
@nl
prefLabel
In vivo antitumor effects of m ...... th A sarcoma malignant ascites
@ast
In vivo antitumor effects of m ...... th A sarcoma malignant ascites
@en
In vivo antitumor effects of m ...... th A sarcoma malignant ascites
@nl
P2093
P3181
P356
P1476
In vivo antitumor effects of m ...... th A sarcoma malignant ascites
@en
P2093
K. Torigoe
K. Yoshida
M. J. Micallef
M. Kurimoto
P2888
P304
P3181
P356
10.1007/S002620050345
P577
1997-01-01T00:00:00Z
P6179
1039614846